SG10201608703SA - Il-6 antagonists and uses thereof - Google Patents

Il-6 antagonists and uses thereof

Info

Publication number
SG10201608703SA
SG10201608703SA SG10201608703SA SG10201608703SA SG10201608703SA SG 10201608703S A SG10201608703S A SG 10201608703SA SG 10201608703S A SG10201608703S A SG 10201608703SA SG 10201608703S A SG10201608703S A SG 10201608703SA SG 10201608703S A SG10201608703S A SG 10201608703SA
Authority
SG
Singapore
Prior art keywords
antagonists
il
uses
Prior art date
Application number
SG10201608703SA
Inventor
Michael M Schmidt
David V Erbe
Thomas M Barnes
Eric Steven Furfine
Alison Tisdale
Original Assignee
Eleven Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261723972P priority Critical
Priority to US201361831699P priority
Application filed by Eleven Biotherapeutics Inc filed Critical Eleven Biotherapeutics Inc
Publication of SG10201608703SA publication Critical patent/SG10201608703SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG10201608703SA 2012-11-08 2013-11-08 Il-6 antagonists and uses thereof SG10201608703SA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201261723972P true 2012-11-08 2012-11-08
US201361831699P true 2013-06-06 2013-06-06

Publications (1)

Publication Number Publication Date
SG10201608703SA true SG10201608703SA (en) 2016-12-29

Family

ID=49876961

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502876RA SG11201502876RA (en) 2012-11-08 2013-11-08 Il-6 antagonists and uses thereof
SG10201608703SA SG10201608703SA (en) 2012-11-08 2013-11-08 Il-6 antagonists and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201502876RA SG11201502876RA (en) 2012-11-08 2013-11-08 Il-6 antagonists and uses thereof

Country Status (16)

Country Link
US (2) US9951130B2 (en)
EP (2) EP2917238A1 (en)
JP (1) JP6480338B2 (en)
KR (1) KR20150079789A (en)
CN (1) CN104903349B (en)
AU (1) AU2013342163B2 (en)
BR (1) BR112015010360A8 (en)
CA (1) CA2886987A1 (en)
HK (1) HK1211599A1 (en)
IL (1) IL238238D0 (en)
MX (1) MX2015005831A (en)
NZ (1) NZ706377A (en)
RU (1) RU2670943C9 (en)
SG (2) SG11201502876RA (en)
WO (1) WO2014074905A1 (en)
ZA (1) ZA201503146B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP3431485A1 (en) 2010-10-01 2019-01-23 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103974724B (en) 2011-10-03 2019-08-30 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
CN104114572A (en) 2011-12-16 2014-10-22 现代治疗公司 Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-03-30 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015517995A (en) 2012-04-02 2015-06-25 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
AU2013342163B2 (en) 2012-11-08 2018-08-16 Sesen Bio, Inc. IL-6 antagonists and uses thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX2016004249A (en) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor.
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
DK3215530T3 (en) * 2014-11-07 2019-11-25 Sesen Bio Inc Improved il-6 antibodies
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
EP3226899A4 (en) * 2014-12-02 2018-09-05 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an il-6r antagonist
KR20180053315A (en) 2015-09-23 2018-05-21 제넨테크, 인크. Optimized variants of anti-VEGF antibodies
AU2017223687A1 (en) * 2016-02-23 2018-08-09 Sesen Bio, Inc. IL-6 antagonist formulations and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0710719T3 (en) 1990-01-12 2007-07-09 Amgen Fremont Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233367D1 (en) 1991-04-10 2004-07-22 Scripps Research Inst Libraries of heterodimer receptors by phagemid
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for antibody screening
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (en) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Device for monitoring a ball mill
TW311927B (en) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69830901T2 (en) 1997-05-02 2006-05-24 Genentech Inc., San Francisco A method for producing multispecific antibodies having heteromultimeric and common components
JP4562286B2 (en) 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー Protein mimetics of antibody mimics and other binding proteins
MXPA02001911A (en) 1999-08-24 2003-07-21 Medarex Inc Human ctla 4 antibodies and their uses.
AT378403T (en) 2000-11-30 2007-11-15 Medarex Inc Tranchromosomal transgen rodents for the manufacture of human antibodies
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1503731A1 (en) 2002-05-07 2005-02-09 Control Delivery Systems, Inc. Processes for forming a drug delivery device
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
CN1947012A (en) * 2003-12-23 2007-04-11 瑞纳神经科学公司 Agonist anti-trkC antibodies and methods using same
KR100864549B1 (en) 2004-08-04 2008-10-20 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Variant fc regions
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AT550353T (en) * 2005-12-30 2012-04-15 Merck Patent Gmbh Binding il-6ralpha-complexed il-6 to gp130 preventing anti-il-6 antibodies
EP2004690A2 (en) * 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JP2009545319A (en) * 2006-08-03 2009-12-24 バクシネックス,インコーポレーテッド Anti-IL-6 monoclonal antibody and use thereof
CA2993715A1 (en) * 2007-05-21 2008-11-27 Alderbio Holdings Llc Antibodies to il-6 and use thereof
AU2009319175A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
EP3124044A1 (en) 2007-09-14 2017-02-01 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
BRPI0820387A2 (en) * 2007-11-21 2015-05-26 Amgen Inc Wise binding agents and epitopes
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2837388A1 (en) * 2008-08-05 2015-02-18 Novartis AG Compositions and methods for antibodies targeting complement protein C5
US20120005773A1 (en) 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
AR079836A1 (en) 2010-01-08 2012-02-22 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibody
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
BR112015008186A2 (en) 2012-10-25 2017-09-19 Medimmune Llc formulation of a stable, low viscosity antibody
AU2013342163B2 (en) 2012-11-08 2018-08-16 Sesen Bio, Inc. IL-6 antagonists and uses thereof

Also Published As

Publication number Publication date
CN104903349B (en) 2018-10-19
WO2014074905A1 (en) 2014-05-15
EP3489258A1 (en) 2019-05-29
BR112015010360A2 (en) 2017-12-05
BR112015010360A8 (en) 2018-01-16
SG11201502876RA (en) 2015-06-29
MX2015005831A (en) 2015-09-24
US20180222975A1 (en) 2018-08-09
JP6480338B2 (en) 2019-03-06
US9951130B2 (en) 2018-04-24
US20150125468A1 (en) 2015-05-07
CA2886987A1 (en) 2014-05-15
AU2013342163A1 (en) 2015-04-16
RU2670943C2 (en) 2018-10-25
JP2016503412A (en) 2016-02-04
NZ706377A (en) 2019-06-28
EP2917238A1 (en) 2015-09-16
KR20150079789A (en) 2015-07-08
CN104903349A (en) 2015-09-09
RU2670943C9 (en) 2018-11-26
RU2015121755A (en) 2016-12-27
HK1211599A1 (en) 2016-05-27
ZA201503146B (en) 2016-02-24
AU2013342163B2 (en) 2018-08-16
IL238238D0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
HK1220373A1 (en) Il-33 antagonists and uses thereof il-33
EP2661839A4 (en) Portable secure element
HK1215183A1 (en) Protein-polymer-drug conjugates --
HK1211039A1 (en) Engineering -cell receptors
EP2888238A4 (en) Benzocyclooctyne compounds and uses thereof
HK1208025A1 (en) Aminoimidazopyridazines
HRP20161774T1 (en) New diazaspirocycloalkane and azaspirocycloalkane
EP2844292A4 (en) St2l antagonists and methods of use
IL238238D0 (en) Il-6 antagonists and uses thereof
EP2754580A4 (en) Dumptruck
HK1203493A1 (en) Substituted azabicycles and use thereof
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
AU343431S (en) Connecting device
IL239643D0 (en) Substituted morphinans and the use thereof
HK1225715A1 (en) Aza-pyridone compounds and uses thereof
IL239369D0 (en) Pirocyclic morphinans and their use
EP2829480A4 (en) Drug-supplying device and drug-counting device
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
BR112014000049A2 (en) hydroxymethylaryl substituted pyrrolotriazines and their use
IL253950D0 (en) Bicyclically substituted uracils and the use thereof
EP2701730A4 (en) Mfg-e8 and uses thereof
GB2501396B (en) Muscle-training pant
PL2906546T3 (en) Benzamides